Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Abstract Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic dat...

詳細記述

書誌詳細

主要な著者:	Keiji Kurata, Anna-James Bott, Mark A. Tye, Leona Yamamoto, Mehmet K. Samur, Yu-Tzu Tai, James Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Udo Oppermann
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Publishing Group 2023-01-01
シリーズ:	Blood Cancer Journal
オンライン･アクセス:	https://doi.org/10.1038/s41408-023-00787-w
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!